Sr Scientist, Drug Metabolism at Gilead Sciences

Foster City, California, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

Bachelor’s Degree and 8 Years’ Experience OR Master’s Degree and 6 Years’ Experience OR PhD/PharmD and 2 Years’ Experience OR MD
Preferred: Ph.D. with 3+ years of post-graduate industry experience in pharmacokinetics, drug metabolism, pharmaceutics, or a related life science field, with a primary focus on quantitative modeling for large molecule/biologics PK characterization across discovery and development
Strong foundation in pharmacokinetics and pharmacodynamics principles, with demonstrated ability to translate these concepts into mathematical models
Extensive experience in mechanistic PK/PKPD modeling

Responsibilities

Provide advanced PK and PK/PD modeling expertise on project teams across discovery and development stages, guiding the design and interpretation of nonclinical PK, toxicology, and pharmacology studies
Lead quantitative DMPK strategy for biologics programs, collaborating with interdisciplinary teams to integrate modeling approaches into decision-making; communicate modeling insights and align strategies with scientists, collaborators, and management
Design, implement, and validate complex PK/PD and mechanistic models to address translational questions, support dose selection, and predict first-in-human exposures
Develop and refine modeling workflows for nonclinical study design, including simulation-based approaches to optimize study parameters and interpret outcomes
Prepare study protocols and coordinate execution of nonclinical studies which may involve multiple functional areas and CROs
Work closely with project teams, line management, and CROs to assure high quality and timely delivery of written PK reports and regulatory documents (IND, IMPD, IB, BLA) for regulatory submissions
Participate in business development and licensing evaluations
Serve as an expert in pharmacokinetic (PK) and PK/PD modeling of biologics, providing strategic and scientific leadership on large molecule discovery and development project teams
Design and interpret in vitro and in vivo studies, integrating data into mathematical models, and generating simulations to support dose selection and clinical translation
Serve as a project representative and departmental modeling expert, contributing to business development initiatives and external collaborations

Skills

PK modeling

PK/PD modeling

biologics DMPK

ADME

mechanistic modeling

empirical modeling

in vitro studies

in vivo studies

mathematical modeling

dose selection

clinical translation

protein therapeutics

Gilead Sciences

Develops and commercializes biopharmaceuticals

About Gilead Sciences

Gilead Sciences focuses on discovering, developing, and commercializing medicines for various medical conditions, including HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular issues. The company conducts extensive research and development to create new therapies, which are then marketed to healthcare providers, hospitals, and pharmacies after receiving regulatory approval. Gilead differentiates itself from competitors through its strong commitment to R&D and strategic partnerships, such as with SAP Ariba, to enhance its operations and product offerings. The company's goal is to improve health equity and access to care globally, working with communities to ensure that its medicines reach those in need.

Foster City, CaliforniaHeadquarters

1987Year Founded

$15,873.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Benefits

Paid family time off and paid parental time off

Generous 401(k) contribution matching

Comprehensive medical plans that cover both physical and mental healthcare

Global Wellbeing Reimbursement

Time Off

Global Volunteer Day

Giving Together Program

Employee Support Programs

Flexible Work Options

Risks

Increased competition in HIV treatment from ViiV Healthcare's expanding drug portfolio.

Regulatory scrutiny over drug pricing could impact Gilead's U.S. market operations.

Patent expirations, like Truvada's, lead to increased generic competition and revenue loss.

Differentiation

Gilead's lenacapavir is recognized as the 2024 Breakthrough of the Year for HIV care.

Partnerships with LEO Pharma and Tubulis enhance Gilead's focus on inflammatory and cancer therapies.

Gilead's commitment to health equity initiatives like COMPASS and HepConnect sets it apart.

Upsides

Gilead's strategic partnerships expand its reach in inflammatory and oncology drug markets.

Investment in digital health technologies enhances Gilead's R&D and patient engagement.

Focus on sustainability improves Gilead's operational efficiency and corporate reputation.

Land your dream remote job 3x faster with AI

Try Jobo Free